A synthetic analog of the immune peptide tuftsin with anxiolytic and nootropic effects — nasal spray administration.
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences (IMGRAN). It is an analog of the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended with additional amino acids to improve stability and bioavailability via the nasal route.
Selank is registered in Russia as an anxiolytic (anti-anxiety) medication under the tradenames Selank® and delivered as a nasal spray. It does not act on GABA receptors like benzodiazepines, producing anxiolytic effects without sedation, cognitive impairment, or addiction potential — characteristics that distinguish it from conventional anti-anxiety medications.
Selank's mechanisms include modulation of the enkephalin system, increased levels of BDNF (brain-derived neurotrophic factor), and immunomodulatory effects through its tuftsin-like core. It also appears to stabilize and potentially increase serotonin metabolism. These multiple mechanisms may explain its combined anxiolytic and nootropic (cognitive-enhancing) effects.
Russian clinical trials demonstrate anxiolytic efficacy comparable to benzodiazepines in anxiety disorders, generalized anxiety, and neurasthenia, without sedation or dependence. Studies show cognitive improvements including enhanced learning, memory consolidation, and mental performance under stress.
Limited Western peer-reviewed literature exists. Most research is in Russian-language journals. BDNF-enhancing effects have been demonstrated in preclinical models. The unique anxiolytic-nootropic profile without sedation is clinically interesting but needs validation in Western clinical trials.
📚 Key Reference: PMID: 19086071 (Selank anxiolytic activity), PMID: 17929762 (BDNF and cognition)
Generally reported as well-tolerated in clinical use. Nasal administration avoids systemic exposure risks of injection. Some users report mild nasal irritation or headache. No significant withdrawal effects or dependence reported — a major advantage over benzodiazepines. Not FDA-approved; consult your provider.
Approved in Russia as an anxiolytic medication. NOT FDA-approved in the US. Available through compounding pharmacies in the US as intranasal preparation. Evidence base is primarily from Russian clinical trials.